Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | SCN8A | Q9UQD0 | 7/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25429394 | 0.84 | HSD17B10 (0.52) | HSD17B10TRPV1 | |
| SCHEMBL25952224 | 0.84 | HSD17B10 (0.39) | HSD17B10TRPV1ALDH1A1BRD4TNKS2 | |
| SCHEMBL25427626 | 0.83 | HSD17B10 (0.51) | HSD17B10TRPV1SCN8ASCN10AALDH1A1 | |
| SCHEMBL25955024 | 0.80 | TRPV1 (0.49) | TRPV1BRD4TNKS2ARSCN9A | |
| SCHEMBL25430647 | 0.78 | HSD17B10 (0.55) | HSD17B10TRPV1ALDH1A1RHEBEPHX2 | |
| SCHEMBL25429117 | 0.78 | HSD17B10 (0.55) | HSD17B10TRPV1ALDH1A1EPHX2 | |
| SCHEMBL25429629 | 0.77 | TRPV1 (0.46) | TRPV1BRD4ARSCN9ASCN5A | |
| SCHEMBL25430366 | 0.77 | TTBK1 (0.42) | HSD17B10SCN8ASCN10ABRD4SCN9A | |
| SCHEMBL25429893 | 0.77 | HSD17B10 (0.54) | HSD17B10TRPV1ALDH1A1 | |
| SCHEMBL9400251 | 0.73 | HSD17B10 (1.00) | HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |